|
Volumn 56, Issue 3, 2001, Pages 163-
|
A step forward in the evidence-based treatment of opportunist mycobacteria
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ETHAMBUTOL;
ISONIAZID;
MACROLIDE;
QUINOLONE DERIVATIVE;
RIFAMPICIN;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG SENSITIVITY;
EDITORIAL;
EVIDENCE BASED MEDICINE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
MYCOBACTERIUM;
MYCOBACTERIUM INTRACELLULARE AVIUM;
MYCOBACTERIUM MALMOENSE;
MYCOBACTERIUM TUBERCULOSIS;
MYCOBACTERIUM XENOPEI;
OPPORTUNISTIC INFECTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
ANTIBIOTICS, ANTITUBERCULAR;
ETHAMBUTOL;
EVIDENCE-BASED MEDICINE;
GREAT BRITAIN;
HUMANS;
MYCOBACTERIUM INFECTIONS;
OPPORTUNISTIC INFECTIONS;
PRACTICE GUIDELINES;
RIFAMPIN;
|
EID: 0035089051
PISSN: 00406376
EISSN: None
Source Type: Journal
DOI: 10.1136/thorax.56.3.163 Document Type: Editorial |
Times cited : (2)
|
References (16)
|